One To Watch

Wave Life Sciences

A clinical-stage RNA medicines company incorporated in Singapore with primary operations in Cambridge, Massachusetts. The company also maintains a broader international footprint to support R&D, clinical execution and corporate operations.

Founding and History

Wave was founded in 2012 and is publicly traded on Nasdaq (WVE). The company has evolved from stereochemistry-focused antisense development into a multi-modality RNA medicines developer spanning RNA editing, gene silencing and splicing/targeted RNA approaches, with a portfolio that includes both rare and more prevalent diseases.

Therapy Areas and Focus

Wave’s disclosed pipeline focus spans:

Metabolic disease, with a lead focus in obesity
Genetic liver and lung disease, notably alpha-1 antitrypsin deficiency (AATD)
CNS and neurodegeneration, notably Huntington’s disease
Muscle disease, including Duchenne muscular dystrophy (programs referenced as part of the broader portfolio)

Technology Platforms and Modalities

Wave’s platform strategy centers on precise oligonucleotide design and chemistry to drive potency, selectivity and tolerability across modalities. Current modalities include:

RNA editing (oligonucleotide-driven editing intended to correct disease-causing RNA sequences)
GalNAc-siRNA for liver-targeted gene silencing
Antisense oligonucleotides, including allele-selective approaches in CNS disease
The company positions its chemistry and design approach as a core differentiator across programs rather than a single-asset thesis.

Key Personnel

Wave’s leadership has been built around RNA medicines development, clinical execution and CMC scale-up. Senior leadership changes disclosed in the last 12–18 months include the appointment of a new Chief Medical Officer in 2025.

Strategic Partnerships

Wave has used partnerships to expand program throughput and share risk. A multi-program collaboration with GSK announced in 2022 included GSK rights to Wave’s AATD RNA editing program. In January 2026, Wave reported that it regained full rights to WVE-006 (AATD) following GSK’s departure from the program, bringing development back in-house.

FAQ Section

Wave develops RNA medicines using engineered oligonucleotides. The platform is designed to support multiple mechanisms—silencing, editing and allele-selective modulation—depending on the disease biology and the target tissue.

Wave’s pipeline concentrates on obesity/metabolic disease, genetic liver/lung disease (AATD), and CNS disease (Huntington’s), with additional programs in genetically defined disorders such as Duchenne muscular dystrophy.

Key disclosed clinical-stage programs include:

WVE-007 (INHBE GalNAc-siRNA) for obesity: Phase I
WVE-006 (RNA editing for AATD): Phase I (RestorAATion-2)
WVE-003 (allele-selective oligonucleotide for Huntington’s disease): Phase I/II
Wave has also referenced additional RNA editing and genetic disease programs at earlier stages.

January 2026: Wave reported that it regained full rights to WVE-006 for AATD after GSK exited the program, and said it would accelerate regulatory engagement and next clinical steps under full ownership.
January 2026 (J.P. Morgan week): Wave outlined 2026 priorities including continued advancement of WVE-007 and acceleration of the RNA editing portfolio.
December 2025: Wave reported positive interim Phase I data for WVE-007 in obesity and guided to additional dose data in 2026.

Recent disclosures have focused on:

WVE-007 Phase I: early human data intended to show pharmacology consistent with targeted fat loss and body-composition effects.
WVE-003 Phase I/II: results disclosed in 2024 supporting allele-selective lowering of mutant huntingtin with preservation of wild-type huntingtin in the studied population.
WVE-006 Phase I: trial progress updates as the program transitions back to full Wave ownership.

Near-term milestones are execution-driven: further Phase I dose data for WVE-007, next-stage planning for WVE-006 in AATD under full control (including FDA engagement referenced by the company), and decisions on the registrational path for WVE-003 following Phase I/II learnings.

Wave positions itself as a multi-modality RNA developer where chemistry and oligonucleotide design are used to tune selectivity, durability and tolerability for different mechanisms (silencing vs editing vs allele-selective modulation). The differentiation case is program-specific and is intended to be demonstrated through human pharmacology and clinical outcomes rather than platform claims alone.

Want to Update your Company's Profile?